Champions Oncology (CSBR) Operating Margin (2010 - 2026)
Champions Oncology (CSBR) recorded quarterly Operating Margin of 1.67% in Q1 2026, down 235.46% quarter-over-quarter from 1.23% in Q4 2025, and down 2807.0% on a YoY basis from 0.06% in Q1 2025.
Champions Oncology (CSBR) Operating Margin (2010 - 2026) Analysis & Trends
Champions Oncology's Operating Margin history runs 17 years deep, the most recent figure standing at 1.67% for Q1 2026.
- In Q1 2026, Operating Margin fell 2807.0% year-over-year to 1.67%; the TTM figure through Jan 2026 stood at 4.53% (down 1526.0% YoY), while the FY2025 annual figure was 8.0%, up 2266.0% from the prior year.
- Operating Margin was 1.67% for Q1 2026 at Champions Oncology, down from 1.23% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 26.4% in Q1 2025 to a low of 21.44% in Q1 2024.
- Historically, Operating Margin has averaged 4.5% across 5 years, with a median of 2.07% in 2022.
- The sharpest annual moves came in 2025 and 2026: Operating Margin surged 4785 bps in 2025, then sank 2807 bps in 2026.
- A 5-year view of Operating Margin shows it stood at 0.05% in 2022, then tumbled by 34564 bps to 16.89% in 2023, then surged by 132 bps to 5.43% in 2024, then plunged by 77 bps to 1.23% in 2025, then tumbled by 235 bps to 1.67% in 2026.
- The last three Operating Margin figures came in at 1.67% (Q1 2026), 1.23% (Q4 2025), and 3.77% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -6.43% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Champions Oncology | 78.46 Mn | 71.46 Mn | 13.89 Mn | -1.67% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2026 | -1.67% |
| Oct 31, 2025 | 1.23% |
| Jul 31, 2025 | -3.77% |
| Apr 30, 2025 | -16.24% |
| Jan 31, 2025 | 26.40% |
| Oct 31, 2024 | 5.43% |
| Jul 31, 2024 | 9.45% |
| Apr 30, 2024 | -1.94% |
| Jan 31, 2024 | -21.44% |
| Oct 31, 2023 | -16.89% |
| Jul 31, 2023 | -20.32% |
| Apr 30, 2023 | -19.29% |
| Jan 31, 2023 | -19.24% |
| Oct 31, 2022 | 0.05% |
| Jul 31, 2022 | -2.07% |
| Apr 30, 2022 | -2.42% |
| Jan 31, 2022 | 6.29% |
| Oct 31, 2021 | 2.23% |
| Jul 31, 2021 | -1.56% |
| Apr 30, 2021 | -6.13% |